收稿日期: 2019-12-03
网络出版日期: 2019-12-25
基金资助
国家自然科学基金(81570444);上海市卫计委第四轮公共卫生行动计划重点学科建设计划(15GWZK0701);上海市科技创新行动计划(17411950602)
蒋荣珍, 钱智敏 . 子痫前期的预测、预防研究现状及进展[J]. 诊断学理论与实践, 2019 , 18(06) : 605 -712 . DOI: 10.16150/j.1671-2870.2019.06.001
| [1] | Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis[J]. BJOG, 2012, 119(7):778-787. |
| [2] | Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia[J]. Clin Chem, 2004, 50(9):1702-1703. |
| [3] | Okwudire EG, Atalabi OM, Ezenwugo UM. The use of uterine artery doppler indices for prediction of pre-eclampsia in Port-Harcourt, Nigeria[J]. Niger Postgrad Med J, 2019, 26(4):223-229. |
| [4] | National Collaborating Centre for Women's and Children's Health (UK). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy[M]. London: RCOG Press, 2010. |
| [5] | ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy[J]. Obstet Gynecol, 2018, 132(1):e44-e52. |
| [6] | Chaemsaithong P, Pooh RK, Zheng M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population[J]. Am J Obstet Gynecol, 2019, 221(6):650. |
| [7] | O'Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations[J]. Ultrasound Obstet Gynecol, 2017, 49(6):756-760. |
| [8] | Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers[J]. Fetal Diagn Ther, 2013, 33(1):8-15. |
| [9] | Tan MY, Wright D, Syngelaki A, et al. Comparison of dia-gnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE[J]. Ultrasound Obstet Gynecol, 2018, 51(6):743-750. |
| [10] | Sonek J, Krantz D, Carmichael J, et al. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volu-me[J]. Am J Obstet Gynecol, 2018, 218(1):126. |
| [11] | Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy[J]. Aust N Z J Obstet Gynaecol, 2013, 53(6):532-539. |
| [12] | O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation[J]. Am J Obstet Gynecol, 2016, 214(1):103. |
| [13] | Krantz DA, Hallahan TW. Incorporating the probability of competing event(s) into the preeclampsia competing risk algorithm[J]. Am J Obstet Gynecol, 2019, 221(5):533-534. |
| [14] | Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia[J]. N Engl J Med, 2017, 377(7):613-622. |
| [15] | Tenório MB, Ferreira RC, Moura FA, et al. Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials[J]. Nutr Metab Cardiovasc Dis, 2018, 28(9):865-876. |
| [16] | Committee on Practice Bulletins—Obstetrics. American College of Obstetricians and Gynecologists′ Committee on Practice Bulletins ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133(1):e1-e25. |
| [17] | Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2018, 13:291-310. |
| [18] | Jiang R, Teng Y, Huang Y, et al. Preeclampsia serum-induced collagen I expression and intracellular calcium levels in arterial smooth muscle cells are mediated by the PLC-γ1 pathway[J]. Exp Mol Med, 2014, 46:e115. |
| [19] | Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4(2):295-306. |
| [20] | Hybiak J, Broniarek I, Kiryczyński G, et al. Aspirin and its pleiotropic application[J]. Eur J Pharmacol, 2020, 866:172762. |
| [21] | Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2018, 218(3):287-293. |
| [22] | 中国高血压防治指南修订委员会, 高血压联盟中国, 中华医学会心血管病学分会, 等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56. |
| [23] | Spracklen CN, Smith CJ, Saftlas AF, et al. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis[J]. Am J Epidemiol, 2014, 180(4):346-358. |
| [24] | Montoro MN, Kjos SL, Chandler M, et al. Insulin resistance and preeclampsia in gestationaldiabetes mellitus[J]. Diabetes Care, 2005, 28(8):1995-2000. |
| [25] | Jin WY, Lin SL, Hou RL, et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China[J]. BMC Pregnancy Childbirth, 2016, 16:60. |
| [26] | 郭晓蒙, 张烨, 王娟, 等. BMI联合血脂对妊娠期高血压及子痫前期的预测价值[J]. 中国妇产科临床杂志, 2019, 20(3):199-201. |
| [27] | Siddiqui F, Kurbasic A, Lindblad U, et al. Effects of a culturally adapted lifestyle intervention on cardio-metabolic outcomes: a randomized controlled trial in Iraqi immigrants to Sweden at high risk for Type 2 diabetes[J]. Metabolism, 2017, 66:1-13. |
| [28] | Assaf-Balut C, García de la Torre N, Fuentes M, et al. A high adherence to six food targets of the mediterranean diet in the late first trimester is associated with a reduction in the risk of materno-foetal Outcomes: The st. carlos gestational diabetes mellitus prevention study[J]. Nutrients, 2018, 11(1) pii: E66. |
| [29] | Muñó z Muñóz A, Gómez-Cantarino S, de Dios Aguado MLM, et al. Nutritional habits and levels of physical activity during pregnancy, birth and the postpartum period of women in Toledo (Spain): study protocol for a two-year prospective cohort study (the PrePaN study)[J]. BMJ Open, 2019, 9(7):e029487. |
| [30] | LeFevre N, Krumm E. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Am Fam Physician, 2019, 100(7):403-405. |
| [31] | Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Cochrane Database Syst Rev, 2018, 10:CD002252. |
| [32] | Pels A, Mol BWJ, Singer J, et al. Influence of gestational age at initiation of antihypertensive therapy: secondary analysis of CHIPS trial data (Control of Hypertension in Pregnancy Study)[J]. Hypertension, 2018, 71(6):1170-1177. |
| [33] | Panaitescu AM, Roberge S, Nicolaides KH. Chronic hypertension: effect of blood pressure control on pregnancy outcome[J]. J Matern Fetal Neonatal Med, 2019, 32(5):857-863. |
| [34] | Magee LA, Singer J, von Dadelszen P, et al. Less-tight versus tight control of hypertension in pregnancy[J]. N Engl J Med, 2015, 372(24):2367-2368. |
| [35] | Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance[J]. BMJ, 2019, 366:l5119. |
| [36] | Yokoyama K, Takahashi N, Yada Y, et al. Prolonged maternal magnesium administration and bone metabolism in neonates[J]. Early Hum Dev, 2010, 86:18 |
| [37] | Altman D, Carroli G, Duley L, et al. Do women with pre- eclampsia, their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placeb o-controlled trial[J]. Lancet, 2002, 359(9321):1877-1890. |
| [38] | Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia[J]. N Engl J Med 2003; 348:304-11. |
| [39] | Trapani A Jr, Gonçalves LF, Trapani TF, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: A randomized controlled trial[J]. Obstet Gynecol, 2016, 128(2):253-259. |
| [40] | Vilchez G, Dai J, Lagos M, et al. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial[J]. J Matern Fetal Neonatal Med, 2018, 31(2):178-183. |
| [41] | Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia[J]. Cochrane Database Syst Rev, 2010, 10(11): CD000025. |
| [42] | Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia[J]. N Engl J Med, 2003, 348:304-311. |
| [43] | Vigil-de Gracia P, Ramirez R, Durán Y, et al. Magnesium sulfate for 6 vs 24 hours post delivery in patients who received magnesium sulfate for less than 8 hours before birth: a randomized clinical trial[J]. BMC Pregnancy Childbirth, 2017, 17(1):241. |
| [44] | Vigil-de Gracia P, Ludmir J, Ng J, et al. Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study[J]. BJOG, 2018, 125(10):1304-1311. |
| [45] | Easterling T, Hebert M, Bracken H, et al. A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion[J]. BMC Pregnancy Childbirth, 2018, 18(1):290. |
| [46] | Pascoal ACF, Katz L, Pinto MH, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial[J]. Medicine, 2019, 98(32):e16779. |
/
| 〈 |
|
〉 |
